Metformin Trial Investigates potential to Slow Abdominal aortic Aneurysm Growth
Table of Contents
A clinical trial in the UK is investigating whether metformin,a common medication used to treat type 2 diabetes,can slow the growth of abdominal aortic aneurysms (AAAs). This research offers potential hope for a less invasive approach to managing this potentially life-threatening condition.
What is an Abdominal Aortic Aneurysm (AAA)?
An abdominal aortic aneurysm is a bulge or swelling in the aorta, the main artery that carries blood from the heart through the abdomen. AAAs often develop slowly and may not cause symptoms until they become large or rupture. Mayo Clinic – abdominal Aortic aneurysm Rupture is a medical emergency, and early detection and management are crucial. Risk factors for AAA include age, smoking, high blood pressure, family history, and atherosclerosis (plaque buildup in the arteries).
The UK clinical Trial & Metformin
The trial, led by Professor Matt Brown at the University of Leicester, is exploring the potential benefits of metformin in slowing AAA progression. The trial involves patients like Mr. Gosling, who was referred after being diagnosed with a 4cm AAA. Participants receive either metformin or a placebo, with regular monitoring of their AAA size.
Metformin’s potential benefit stems from its anti-inflammatory and vascular protective properties. Research suggests it may reduce the breakdown of collagen,a key protein in artery walls,potentially slowing aneurysm growth. University of Leicester News – Metformin trial for abdominal aortic aneurysms
Why is this research important?
Currently, management of medium to large AAAs often involves surgical repair or endovascular aneurysm repair (EVAR), both of which carry risks. If metformin proves effective, it could offer a medical management option to delay or even prevent the need for intervention. This is particularly appealing for patients who are not ideal candidates for surgery due to other health conditions.
Trial Phases and Patient Experience
The trial is conducted in phases. Initially, patients are given gradually increasing doses of metformin to assess tolerance. Following this, they are randomized to receive either metformin or a placebo, with regular monitoring via imaging scans to track AAA growth.Participants, like Mr. Gosling, may need to adjust their activities, such as avoiding heavy lifting, during the trial.
Current Status and Future Outlook
The trial is ongoing,and results are eagerly awaited. Researchers hope to determine whether metformin can significantly slow AAA growth and improve patient outcomes. Further research will be needed to confirm these findings and establish optimal dosing and patient selection criteria.
primary Topic: Abdominal Aortic Aneurysms and Metformin Clinical Trial
Primary Keyword: Abdominal Aortic Aneurysm (AAA)
Secondary Keywords: Metformin, AAA treatment, vascular disease, aneurysm repair, clinical trial, aortic aneurysm, vascular health, aneurysm growth, abdominal pain, aortic dilation.
Related reading